Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 1,136B | 100202017.3% |
| Gross Profit | -136B | 84726126.6% |
| Cost of Revenue | 1,272B | 98282282.6% |
| Operating expense | 624B | 69698206.9% |
| Net Income | -786B | 64157974.9% |
| EBITDA | -759B | 101605786.7% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 14,217B | 95496458.1% |
| Total Liabilities | 7,247B | 101507053% |
| Total Equity | 6,970B | 89957751.8% |
| Shares Outstanding | 3.26B | 18578.2% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -57.8B | 24246768.4% |
| Cash from financing | -70B | 1029594337% |
EPS
Financial Highlights for China Pharma Holding in Q1 '25
China Pharma Holding reported a revenue of 1,136B, which is a 100202017.3% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -136B, marking a -84726126.6% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 1,272B, a 98282282.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 624B, showing a 69698206.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -786B, showing a -64157974.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -759B, showing a -101605786.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
China Pharma Holding faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
